Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick R Verhoest

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Bioorganic & Medicinal Chemistry Letters|March 8, 2013
PF-04859989 as a template for structure-based drug design: identification of new pyrazole series of irreversible KAT II inhibitors with improved lipophilic efficiencyAmy B Dounay, Marie Anderson, Bruce M Bechle, et al.
Bioorganic & Medicinal Chemistry Letters|August 13, 2014
Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffoldPaul Galatsis, Jaclyn L Henderson, Bethany L Kormos, et al.
Journal of Medicinal Chemistry|July 13, 2011
Design and discovery of a selective small molecule κ opioid antagonist (2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242)Patrick R Verhoest, Aarti Sawant Basak, Vinod Parikh, et al.
Journal of Medicinal Chemistry|July 28, 2009
Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophreniaPatrick R Verhoest, Douglas S Chapin, Michael Corman, et al.
Journal of Medicinal Chemistry|May 9, 2013
Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligandLei Zhang, Anabella Villalobos, Elizabeth M Beck, et al.
Journal of Medicinal Chemistry|October 30, 2014
Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitorJaclyn L Henderson, Bethany L Kormos, Matthew M Hayward, et al.
Journal of Medicinal Chemistry|July 12, 2012
Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disordersPatrick R Verhoest, Kari R Fonseca, Xinjun Hou, et al.
Journal of Medicinal Chemistry|November 19, 2009
Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategyPatrick R Verhoest, Caroline Proulx-Lafrance, Michael Corman, et al.
Bioorganic & Medicinal Chemistry Letters|January 14, 2015
Discovery of indole-derived pyridopyrazine-1,6-dione γ-secretase modulators that target presenilinMartin Pettersson, Douglas S Johnson, John M Humphrey, et al.
Journal of Medicinal Chemistry|February 18, 2014
1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)indoline-4-carbonitrile derivatives as potent and tissue selective androgen receptor modulatorsEugene L Piatnitski Chekler, Rayomond Unwalla, Taukeer A Khan, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Bioorganic & Medicinal Chemistry Letters|March 8, 2013
PF-04859989 as a template for structure-based drug design: identification of new pyrazole series of irreversible KAT II inhibitors with improved lipophilic efficiencyAmy B Dounay, Marie Anderson, Bruce M Bechle, et al.
Bioorganic & Medicinal Chemistry Letters|August 13, 2014
Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffoldPaul Galatsis, Jaclyn L Henderson, Bethany L Kormos, et al.
Journal of Medicinal Chemistry|July 13, 2011
Design and discovery of a selective small molecule κ opioid antagonist (2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242)Patrick R Verhoest, Aarti Sawant Basak, Vinod Parikh, et al.
Journal of Medicinal Chemistry|July 28, 2009
Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophreniaPatrick R Verhoest, Douglas S Chapin, Michael Corman, et al.
Journal of Medicinal Chemistry|May 9, 2013
Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligandLei Zhang, Anabella Villalobos, Elizabeth M Beck, et al.
Journal of Medicinal Chemistry|October 30, 2014
Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitorJaclyn L Henderson, Bethany L Kormos, Matthew M Hayward, et al.
Journal of Medicinal Chemistry|July 12, 2012
Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disordersPatrick R Verhoest, Kari R Fonseca, Xinjun Hou, et al.
Journal of Medicinal Chemistry|November 19, 2009
Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategyPatrick R Verhoest, Caroline Proulx-Lafrance, Michael Corman, et al.
Bioorganic & Medicinal Chemistry Letters|January 14, 2015
Discovery of indole-derived pyridopyrazine-1,6-dione γ-secretase modulators that target presenilinMartin Pettersson, Douglas S Johnson, John M Humphrey, et al.
Journal of Medicinal Chemistry|February 18, 2014
1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)indoline-4-carbonitrile derivatives as potent and tissue selective androgen receptor modulatorsEugene L Piatnitski Chekler, Rayomond Unwalla, Taukeer A Khan, et al.
Pageof 4